bioAffinity Technologies, Inc. — Director's Dealing 2024

Feb 2, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2024-01-31

Reporting Person: Zannes Maria (Director, President, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-31	Common Stock	A	23885	—	Acquired	164658	Direct

Footnotes

F1: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024.